Viking Therapeutics, Inc. (0VQA.L) LSE

Currency In USD

Viking Therapeutics, Inc.

Address

9920 Pacific Heights Boulevard

San Diego, CA 92121

United States of America (the)

Phone

858 704 4660

Website

https://www.vikingtherapeutics.com

Sector

Healthcare

Industry

Biotechnology

Employees

First IPO Date

October 08, 2018

Key Executives

Name	Title	Pay	Year Born
Brian Lian	President, Chief Executive Officer & Director	1.05M	1966
Michael Morneau	Vice President of Finance & Administration	375,333	1965
Gregory S. Zante	Chief Financial Officer	738,000	1971
Marianne Mancini	Chief Operating Officer	765,000	1965
Kenneth Herman	Senior Vice President of Commercial, Marketing & Sales	0	N/A
Neil Aubuchon	Chief Commercial Officer	0	1971
Katherine Mercier	Vice President of Quality and Compliance	0	N/A
Geoffrey E. Barker	Chief Development Officer	0	N/A
Nils U. Olsson	Senior Vice President of Technical Operations	0	N/A

Description

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to developing innovative therapies for metabolic and endocrine disorders. Its flagship product candidate, VK2809, is an orally administered, tissue- and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). Currently, VK2809 is undergoing Phase IIb clinical trials to address non-alcoholic steatohepatitis (NASH) confirmed by biopsy, as well as non-alcoholic fatty liver disease (NAFLD). The company's pipeline further features VK5211, an orally available non-steroidal selective androgen receptor modulator, which is in Phase II trials for patients convalescing from non-elective hip fracture surgery. Additionally, VK0612, an oral candidate poised for Phase IIb evaluation, targets type 2 diabetes. Lastly, VK0214, another orally administered TRß selective agonist, is being developed for X-linked adrenoleukodystrophy. Established in 2012, Viking Therapeutics maintains its corporate headquarters in San Diego, California.